Protara Therapeutics, Inc.

NASDAQ:TARA

Biotechnology

Healthcare
$2.34 -1.27%

-$0.05 today

Market cap
$144.07M
Beta
1.45
P/E (TTM)
-2.7
EPS (TTM)
-$1.48
52W Low $2.77High $7.82

Volume 1.15M

Average 0.73M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$56.37M

FY 2025 · Annual

Investing Cash Flow

-$139.49M

FY 2025 · Annual

Financing Cash Flow

$82.72M

FY 2025 · Annual

-40.9% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(47.25M)(65.95M)(40.42M)(44.6M)(57.44M)
Depreciation & Amortization117K248K341K332K362K
Deferred Income Tax00000
Stock-Based Compensation10.36M6.69M6.09M4.13M3.83M
Change in Working Capital534K539K(4.14M)4.01M(2.94M)
Accounts Receivables00000
Inventory00000
Accounts Payables40K631K848K1.38M(873K)
Other Working Capital494K(92K)(4.99M)2.63M(2.07M)
Other Non-Cash Items1.74M32.02M569K324K(173K)
Operating Cash Flow(34.5M)(26.46M)(37.56M)(35.81M)(56.37M)
Capital Expenditures(596K)(120K)(45K)(63K)(94K)
Acquisitions (Net)97.6K(15.07K)000
Purchases of Investments(124.75M)(43.55M)(12.19M)(29.38M)(204.63M)
Sales of Investments27.15M58.62M65.34M48.6M65.23M
Other Investing Activities(97.6K)15.07K000
Investing Cash Flow(98.19M)14.95M53.11M19.16M(139.49M)
Debt Repayment00000
Common Stock Issued000136.01M82.9M
Common Stock Repurchased(228K)(90K)(91K)00
Dividends Paid00000
Other Financing Activities0003.86M(185K)
Financing Cash Flow(228K)(90K)(91K)139.87M82.72M
Effect of Forex Changes00000
Net Change in Cash(132.92M)(11.6M)15.46M123.21M(113.14M)
Free Cash Flow(35.1M)(26.58M)(37.6M)(35.87M)(56.46M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$57.4M
+ D&A$362.0K
+ Stock-Based Comp$3.8M
+ Deferred Tax$0
- Working Capital-$2.9M
- Other Non-Cash-$173.0K
= Operating Cash Flow-$56.4M
- Capex-$94.0K
= Free Cash Flow-$56.5M

Analysis

FY2025 free cash flow is -$56.5M. FCF conversion is 98.3% of net income. Operating cash flow was -$56.4M, with capex of -$94.0K. The largest bridge item is Stock-Based Comp at $3.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 6, 2026
10-QQuarterly reportNov 6, 2026
SC 13G/ASC 13G/A filingAug 13, 2026
8-KCurrent reportAug 11, 2026
S-8S-8 filingAug 11, 2026

Does TARA generate free cash flow?

Protara Therapeutics, Inc. (TARA) generated -$56.46M of free cash flow in fiscal 2025.

How much operating cash flow does TARA produce?

Operating cash flow was -$56.37M, before capital expenditures of $94,000.00.